Last reviewed · How we verify
GB10
At a glance
| Generic name | GB10 |
|---|---|
| Sponsor | Shenzhen Kexing Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) (PHASE1)
- Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GB10 CI brief — competitive landscape report
- GB10 updates RSS · CI watch RSS
- Shenzhen Kexing Pharmaceutical Co., Ltd. portfolio CI